Arsenic Trioxide for Induction Therapy of Adult Patients With Leukemia
Status:
Terminated
Trial end date:
2003-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients
who have recurrent or refractory acute lymphoblastic leukemia or chronic myelogenous
leukemia.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute